Please ensure Javascript is enabled for purposes of website accessibility

FDA Gives Bristol-Myers Squibb's CAR-T Liso-Cel a Priority Review

By Brian Orelli, PhD - Feb 13, 2020 at 11:46AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A decision on the cancer therapy is expected by Aug. 17.

The Food and Drug Administration is giving a priority review to lisocabtagene maraleucel (liso-cel), a CAR-T (chimeric antigen receptor T-cell) therapy from Bristol-Myers Squibb (BMY 1.64%). The agency plans to make a decision on the marketing application by Aug. 17, four months earlier than it would have under the standard review process.

Like other CAR-T therapies being developed by various biotech companies, liso-cel involves taking immune cells from the patient, manipulating them so they target lymphoma cells that express a specific protein -- in this case, one called CD19 -- and then putting them back into the patient, where they attack the blood cancer.

Doctor talking to a patient in front of a window

Image source: Getty Images.

Bristol-Myers Squibb acquired liso-cel through its purchase of Celgene, which in turn had gained it via its purchase of Juno Therapeutics. Liso-cel would be the first treatment developed by Juno to gain FDA approval, but the BMS subsidiary has a full pipeline of CAR-T therapies, as well as therapies incorporating a related technique that uses the T-cell receptor to target immune cells to tumor cells.

The marketing application is based on the Transcend NHL 001 clinical trial, in which 73% of the 256 treated patients responded to liso-cel, including 53% who had a complete response. Patients lived for a median of 21.1 months, quite an accomplishment considering that multiple other therapies had failed the patients in the study.

Former Celgene shareholders will want to keep a close eye on the approval since it's part of a contingent value right (CVR) that could result in an additional $9 payment for each CVR held if liso-cel and two other drugs are approved.

If it's approved, liso-cel will join two CAR-T treatments that have already gained FDA approval to treat types of lymphoma: Novartis' Kymriah and Gilead Sciences' Yescarta.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$78.96 (1.64%) $1.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.